On September 8, 2021, CHAI (Clinton Health Access Initiative Indonesia) held a webinar and released a Market Report on HCV.
This report provides a report on hepatitis C (HCV) diagnosis and treatment in low- and middle-income countries to help guide the elimination of Hepatitis C.
On this occasion, Peduli Hati Bangsa, represented by Caroline Thomas as the Founder, was asked to provide insights from the community in the webinar. The topic raised was the reduction in the price of DAA (Direct Acting Antivirus) in Indonesia.
Peduli Hati Bangsa works to increase awareness and access to the diagnosis and treatment of Hepatitis in Indonesia. In recent years, communities affected by the Hepatitis issue have also succeeded in advocating for the availability of DAA at affordable prices in Indonesia. The community also continues to play a role in micro-elimination of Hepatitis C, including in prisons and detention centers in Indonesia.
Some important points summarized in Caroline’s presentation at this meeting are:
- Currently the Government of Indonesia has provided a free Hepatitis C treatment program using Sofosbuvir and Daclatasvir.
- The price of Sofosbuvir and Daclatasvir purchased by the Government of Indonesia through e-catalog continues to decline. One of them is because there is competition from generic companies that register their products in Indonesia.
- The government is able to buy medicine for around 5,500 to 6,000 people per year. However, to achieve elimination, Indonesia must continue to increase its diagnostic and treatment efforts.
- Analysis shows that reducing the price of DAA to USD 150 per treatment course and reducing the price of viral load testing to USD 40 could reduce the total cost of the Government’s program by as much as USD 150. 60% from USD 4.3 billion to USD 1.7 billion.
- Elimination of HCV will prevent at least 1 million new infections by 2040.
More on CHAI at https://chaiindonesia.org/